Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Dickson

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety UpdateAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2015
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomasMrinal Gounder, Ved Desai, Deborah Kuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2021
<i>nab</i>-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell TumorsAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2023
Stereotactic body radiation therapy for sarcoma pulmonary metastasesEmily S Lebow, Stephanie M Lobaugh, Zhigang Zhang, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus IpilimumabSandra P D'Angelo, Alexander N Shoushtari, Mary Louise Keohan, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2024
Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety UpdateAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer Medicine|June 21, 2026
Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II TrialsAdel Shahnam, Kristen DiConza, Simran Jasnani, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2015
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomasMrinal Gounder, Ved Desai, Deborah Kuk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2021
<i>nab</i>-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell TumorsAndrew J Wagner, Vinod Ravi, Richard F Riedel, et al.
Cancer Research Communications|October 3, 2023
Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced SarcomasEvan Rosenbaum, Kenneth Seier, Martina Bradic, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 2, 2023
Stereotactic body radiation therapy for sarcoma pulmonary metastasesEmily S Lebow, Stephanie M Lobaugh, Zhigang Zhang, et al.
Investigational New Drugs|August 14, 2018
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumorCiara M Kelly, Alexander N Shoushtari, Li-Xuan Qin, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2016
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus IpilimumabSandra P D'Angelo, Alexander N Shoushtari, Mary Louise Keohan, et al.
Pageof 8